REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – An emerging metric in MS research is the proportion of patients who are disease-activity free (DAF), defined as no relapses, no MRI activity (T2 or Gd+ T1 lesions) and no sustained EDSS progression. One of the first uses was an analysis of the AFFIRM dataset, which reported a two-year DAF rate of 37% with natalizumab versus 7% with placebo (Havrdova et al. Lancet Neurol 2009;8:254-260).
Latest News
Second-line switching: three reports
March 23, 2013REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – Natalizumab is commonly used following first-line treatment failure/intolerance, but switching may be advisable after two years in patients with anti-JC virus antibody positivity. However, switching therapies is challenging in practice due to the risk of increased disease activity upon natalizumab withdrawal.
CCSVI: has the balloon burst?
March 23, 2013REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – An Alberta study reports that patients’ interest in venoplasty to treat chronic cerebrospinal venous insufficiency (CCSVI) appears to be on the decline (Metz et al. AAN 2013; abstract P05.183).
BG-12: two analyses of safety results
March 22, 2013REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – An integrated analysis of BG-12 trials indicates that there is a low incidence of serious adverse events during treatment although flushing and gastrointestinal effects are common (Phillips et al. AAN 2013; abstract S30.003).